Subchronic hepatotoxicity evaluation of bromobenzene in Fischer 344 rats
ABSTRACT Male Fischer 344 (F344) rats were exposed to bromobenzene (BB) for 5 days and 2, 4 and 13 weeks. BB was administered by gavage (corn oil vehicle) at doses of 0, 25, 100, 200, 300 and 400 mg kg−1 per day. Endpoints evaluated included clinical observations, body weights, liver weights, serum...
Saved in:
Published in: | Journal of applied toxicology Vol. 33; no. 5; pp. 370 - 377 |
---|---|
Main Authors: | , , , , |
Format: | Journal Article |
Language: | English |
Published: |
England
Blackwell Publishing Ltd
01-05-2013
Wiley Subscription Services, Inc |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | ABSTRACT
Male Fischer 344 (F344) rats were exposed to bromobenzene (BB) for 5 days and 2, 4 and 13 weeks. BB was administered by gavage (corn oil vehicle) at doses of 0, 25, 100, 200, 300 and 400 mg kg−1 per day. Endpoints evaluated included clinical observations, body weights, liver weights, serum chemistry, blood BB, gross pathology and liver histopathology. There were no BB exposure‐related clinical signs of toxicity. Mean body weight decreased by 5–10% compared with control in the 400 mg kg−1 per day group. Liver weight increases were dose‐ and exposure time‐related and statistically significant at ≥25 mg kg−1 per day. Incidence and severity of centrilobular cytoplasmic alteration and hepatocyte hypertrophy were related to dose and exposure time. At early time points (5 days and 2 weeks), centrilobular inflammation, including granulomatous areas, and necrotic and anisokaryocytic hepatocytes were observed in rats of the two highest BB dose groups. Blood BB concentrations increased linearly with dose and at 13 weeks ranged from 8 to 136 µg ml−1 (25–400 mg kg−1 per day). In conclusion, rats administered BB doses up to 400 mg kg−1 per day for up to 13 weeks had mild liver effects. A NOAEL of 200 mg kg−1 per day was selected based on the statistically significant incidence of hepatocyte hypertrophy at doses ≥ 400 mg kg−1 per day. Copyright © 2012 John Wiley & Sons, Ltd.
Male Fischer 344 rats were administered bromobenzene by gavage at 0, 25, 100, 200, 300, or 400 mg kg−1 per day for 5 days and 2, 4 and 13 weeks. Mean body weight decreased 5‐10% at 400 mg kg−1 per day. Liver weight increases were dose‐ and exposure time‐related and significant at ≥25 mg kg−1 per day. Incidence and severity of centrilobular cytoplasmic alteration and hepatocyte hypertrophy were also related to dose and exposure time. A NOAEL of 200 mg kg−1 per day was selected based on a statistically significant increase in hypertrophy at ≥400 mg kg−1 per day. |
---|---|
AbstractList | Male Fischer 344 (F344) rats were exposed to bromobenzene (BB) for 5days and 2, 4 and 13weeks. BB was administered by gavage (corn oil vehicle) at doses of 0, 25, 100, 200, 300 and 400mgkg-1 per day. Endpoints evaluated included clinical observations, body weights, liver weights, serum chemistry, blood BB, gross pathology and liver histopathology. There were no BB exposure-related clinical signs of toxicity. Mean body weight decreased by 5-10% compared with control in the 400mgkg-1 per day group. Liver weight increases were dose- and exposure time-related and statistically significant at ≥25mgkg-1 per day. Incidence and severity of centrilobular cytoplasmic alteration and hepatocyte hypertrophy were related to dose and exposure time. At early time points (5days and 2weeks), centrilobular inflammation, including granulomatous areas, and necrotic and anisokaryocytic hepatocytes were observed in rats of the two highest BB dose groups. Blood BB concentrations increased linearly with dose and at 13weeks ranged from 8 to 136µgml-1 (25-400mgkg-1 per day). In conclusion, rats administered BB doses up to 400mgkg-1 per day for up to 13weeks had mild liver effects. A NOAEL of 200mgkg-1 per day was selected based on the statistically significant incidence of hepatocyte hypertrophy at doses≥400mgkg-1 per day. Copyright © 2012 John Wiley & Sons, Ltd. Male Fischer 344 rats were administered bromobenzene by gavage at 0, 25, 100, 200, 300, or 400mgkg-1 per day for 5days and 2, 4 and 13weeks. Mean body weight decreased 5-10% at 400mgkg-1 per day. Liver weight increases were dose- and exposure time-related and significant at ≥25mgkg-1 per day. Incidence and severity of centrilobular cytoplasmic alteration and hepatocyte hypertrophy were also related to dose and exposure time. A NOAEL of 200mgkg-1 per day was selected based on a statistically significant increase in hypertrophy at ≥400mgkg-1 per day. [PUBLICATION ABSTRACT] Male Fischer 344 (F344) rats were exposed to bromobenzene (BB) for 5days and 2, 4 and 13weeks. BB was administered by gavage (corn oil vehicle) at doses of 0, 25, 100, 200, 300 and 400mgkg super(-1) per day. Endpoints evaluated included clinical observations, body weights, liver weights, serum chemistry, blood BB, gross pathology and liver histopathology. There were no BB exposure-related clinical signs of toxicity. Mean body weight decreased by 5-10% compared with control in the 400mgkg super(-1) per day group. Liver weight increases were dose- and exposure time-related and statistically significant at greater than or equal to 25mgkg super(-1) per day. Incidence and severity of centrilobular cytoplasmic alteration and hepatocyte hypertrophy were related to dose and exposure time. At early time points (5days and 2weeks), centrilobular inflammation, including granulomatous areas, and necrotic and anisokaryocytic hepatocytes were observed in rats of the two highest BB dose groups. Blood BB concentrations increased linearly with dose and at 13weeks ranged from 8 to 136 mu gml super(-1) (25-400mgkg super(-1) per day). In conclusion, rats administered BB doses up to 400mgkg super(-1) per day for up to 13weeks had mild liver effects. A NOAEL of 200mgkg super(-1) per day was selected based on the statistically significant incidence of hepatocyte hypertrophy at doses greater than or equal to 400mgkg super(-1) per day. Copyright [copy 2012 John Wiley & Sons, Ltd. Male Fischer 344 rats were administered bromobenzene by gavage at 0, 25, 100, 200, 300, or 400mgkg super(-1) per day for 5days and 2, 4 and 13weeks. Mean body weight decreased 5-10% at 400mgkg super(-1) per day. Liver weight increases were dose- and exposure time-related and significant at greater than or equal to 25mgkg super(-1) per day. Incidence and severity of centrilobular cytoplasmic alteration and hepatocyte hypertrophy were also related to dose and exposure time. A NOAEL of 200mgkg super(-1) per day was selected based on a statistically significant increase in hypertrophy at greater than or equal to 400mgkg super(-1) per day. Male Fischer 344 (F344) rats were exposed to bromobenzene (BB) for 5 days and 2, 4 and 13 weeks. BB was administered by gavage (corn oil vehicle) at doses of 0, 25, 100, 200, 300 and 400 mg kg(-1) per day. Endpoints evaluated included clinical observations, body weights, liver weights, serum chemistry, blood BB, gross pathology and liver histopathology. There were no BB exposure-related clinical signs of toxicity. Mean body weight decreased by 5-10% compared with control in the 400 mg kg(-1) per day group. Liver weight increases were dose- and exposure time-related and statistically significant at ≥25 mg kg(-1) per day. Incidence and severity of centrilobular cytoplasmic alteration and hepatocyte hypertrophy were related to dose and exposure time. At early time points (5 days and 2 weeks), centrilobular inflammation, including granulomatous areas, and necrotic and anisokaryocytic hepatocytes were observed in rats of the two highest BB dose groups. Blood BB concentrations increased linearly with dose and at 13 weeks ranged from 8 to 136 µg ml(-1) (25-400 mg kg(-1) per day). In conclusion, rats administered BB doses up to 400 mg kg(-1) per day for up to 13 weeks had mild liver effects. A NOAEL of 200 mg kg(-1) per day was selected based on the statistically significant incidence of hepatocyte hypertrophy at doses ≥ 400 mg kg(-1) per day. Male Fischer 344 (F344) rats were exposed to bromobenzene (BB) for 5 days and 2, 4 and 13 weeks. BB was administered by gavage (corn oil vehicle) at doses of 0, 25, 100, 200, 300 and 400 mg kg −1 per day. Endpoints evaluated included clinical observations, body weights, liver weights, serum chemistry, blood BB, gross pathology and liver histopathology. There were no BB exposure‐related clinical signs of toxicity. Mean body weight decreased by 5–10% compared with control in the 400 mg kg −1 per day group. Liver weight increases were dose‐ and exposure time‐related and statistically significant at ≥25 mg kg −1 per day. Incidence and severity of centrilobular cytoplasmic alteration and hepatocyte hypertrophy were related to dose and exposure time. At early time points (5 days and 2 weeks), centrilobular inflammation, including granulomatous areas, and necrotic and anisokaryocytic hepatocytes were observed in rats of the two highest BB dose groups. Blood BB concentrations increased linearly with dose and at 13 weeks ranged from 8 to 136 µg ml −1 (25–400 mg kg −1 per day). In conclusion, rats administered BB doses up to 400 mg kg −1 per day for up to 13 weeks had mild liver effects. A NOAEL of 200 mg kg −1 per day was selected based on the statistically significant incidence of hepatocyte hypertrophy at doses ≥ 400 mg kg −1 per day. Copyright © 2012 John Wiley & Sons, Ltd. Male Fischer 344 rats were administered bromobenzene by gavage at 0, 25, 100, 200, 300, or 400 mg kg −1 per day for 5 days and 2, 4 and 13 weeks. Mean body weight decreased 5‐10% at 400 mg kg −1 per day. Liver weight increases were dose‐ and exposure time‐related and significant at ≥25 mg kg −1 per day. Incidence and severity of centrilobular cytoplasmic alteration and hepatocyte hypertrophy were also related to dose and exposure time. A NOAEL of 200 mg kg −1 per day was selected based on a statistically significant increase in hypertrophy at ≥400 mg kg −1 per day. ABSTRACT Male Fischer 344 (F344) rats were exposed to bromobenzene (BB) for 5 days and 2, 4 and 13 weeks. BB was administered by gavage (corn oil vehicle) at doses of 0, 25, 100, 200, 300 and 400 mg kg−1 per day. Endpoints evaluated included clinical observations, body weights, liver weights, serum chemistry, blood BB, gross pathology and liver histopathology. There were no BB exposure‐related clinical signs of toxicity. Mean body weight decreased by 5–10% compared with control in the 400 mg kg−1 per day group. Liver weight increases were dose‐ and exposure time‐related and statistically significant at ≥25 mg kg−1 per day. Incidence and severity of centrilobular cytoplasmic alteration and hepatocyte hypertrophy were related to dose and exposure time. At early time points (5 days and 2 weeks), centrilobular inflammation, including granulomatous areas, and necrotic and anisokaryocytic hepatocytes were observed in rats of the two highest BB dose groups. Blood BB concentrations increased linearly with dose and at 13 weeks ranged from 8 to 136 µg ml−1 (25–400 mg kg−1 per day). In conclusion, rats administered BB doses up to 400 mg kg−1 per day for up to 13 weeks had mild liver effects. A NOAEL of 200 mg kg−1 per day was selected based on the statistically significant incidence of hepatocyte hypertrophy at doses ≥ 400 mg kg−1 per day. Copyright © 2012 John Wiley & Sons, Ltd. Male Fischer 344 rats were administered bromobenzene by gavage at 0, 25, 100, 200, 300, or 400 mg kg−1 per day for 5 days and 2, 4 and 13 weeks. Mean body weight decreased 5‐10% at 400 mg kg−1 per day. Liver weight increases were dose‐ and exposure time‐related and significant at ≥25 mg kg−1 per day. Incidence and severity of centrilobular cytoplasmic alteration and hepatocyte hypertrophy were also related to dose and exposure time. A NOAEL of 200 mg kg−1 per day was selected based on a statistically significant increase in hypertrophy at ≥400 mg kg−1 per day. |
Author | Pluta, Linda J. Banas, Deborah A. Thomas, Russell S. Dodd, Darol E. Sochaski, Mark A. |
Author_xml | – sequence: 1 givenname: Darol E. surname: Dodd fullname: Dodd, Darol E. organization: The Hamner Institutes for Health Sciences, Research Triangle Park, NC, USA – sequence: 2 givenname: Linda J. surname: Pluta fullname: Pluta, Linda J. organization: The Hamner Institutes for Health Sciences, Research Triangle Park, NC, USA – sequence: 3 givenname: Mark A. surname: Sochaski fullname: Sochaski, Mark A. organization: The Hamner Institutes for Health Sciences, Research Triangle Park, NC, USA – sequence: 4 givenname: Deborah A. surname: Banas fullname: Banas, Deborah A. organization: Experimental Pathology Laboratories, Inc., Research Triangle Park, NC, USA – sequence: 5 givenname: Russell S. surname: Thomas fullname: Thomas, Russell S. email: Correspondence to: Russell Thomas, The Hamner Institutes for Health Sciences, Research Triangle Park, NC, USA., rthomas@thehamner.org organization: The Hamner Institutes for Health Sciences, Research Triangle Park, NC, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22407932$$D View this record in MEDLINE/PubMed |
BookMark | eNqF0U1LHDEYwPEglrraQj-BDPTSy9jkSTJJjrL40rK2oJZKLyGZybDZziZrMtO6fnpncatQEE855MefJ3n20W6IwSH0geAjgjF8Xpj-CASFHTQhWKmSQEV30QRDhUtGxc0e2s95gfF4B_It2gNgWCgKE3R-Ndh6nmLwdTF3K9PHPt752vfrwv0x3WB6H0MR28KmuIzWhXsXXOFDcepzPXepoIwVyfT5HXrTmi6799vzAP04Pbmenpez72dfpsezsuYcoOTCNtjWjWENtMwoizkhQjELnBMpuOIEN7i1vKISZOtcI1RbCWANJYpLTg_Qp8fuKsXbweVeL8dJXNeZ4OKQNRGccsoIh9cpowqAMNhUP_5HF3FIYXzIRjEppaLqOVinmHNyrV4lvzRprQnWm0XocRF6s4iRHm6Dg1265gn--_kRlI_gr-_c-sWQ_np8vQ1uvc-9u3vyJv3WlaCC65_fzrScXdxcXv2a6gv6AMgKoAM |
CitedBy_id | crossref_primary_10_1021_acs_chemrestox_0c00387 crossref_primary_10_1007_s00204_016_1886_5 crossref_primary_10_1016_j_aquatox_2014_11_002 crossref_primary_10_1093_toxsci_kft249 |
Cites_doi | 10.1093/mutage/2.2.111 10.1177/019262338501300404 10.1016/0272-0590(84)90241-0 |
ContentType | Journal Article |
Copyright | Copyright © 2012 John Wiley & Sons, Ltd. Copyright © 2013 John Wiley & Sons, Ltd. |
Copyright_xml | – notice: Copyright © 2012 John Wiley & Sons, Ltd. – notice: Copyright © 2013 John Wiley & Sons, Ltd. |
DBID | BSCLL CGR CUY CVF ECM EIF NPM AAYXX CITATION 7ST 7TK 7U7 C1K K9. SOI 8FD FR3 KR7 |
DOI | 10.1002/jat.2732 |
DatabaseName | Istex Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Environment Abstracts Neurosciences Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management ProQuest Health & Medical Complete (Alumni) Environment Abstracts Technology Research Database Engineering Research Database Civil Engineering Abstracts |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest Health & Medical Complete (Alumni) Toxicology Abstracts Neurosciences Abstracts Environment Abstracts Environmental Sciences and Pollution Management Technology Research Database Civil Engineering Abstracts Engineering Research Database |
DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) Technology Research Database Toxicology Abstracts MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Public Health Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1099-1263 |
EndPage | 377 |
ExternalDocumentID | 3079189101 10_1002_jat_2732 22407932 JAT2732 ark_67375_WNG_8LMXRSZC_M |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 31~ 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52S 52T 52U 52W 52X 53G 5GY 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABEFU ABEML ABIJN ABJNI ABPVW ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFNX AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHMBA AI. AIAGR AITYG AIURR AIWBW AJBDE AJXKR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AUFTA AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMNLL BMXJE BNHUX BROTX BRXPI BSCLL BY8 CS3 D-E D-F DCZOG DPXWK DR2 DRFUL DRSTM EBD EBS EDH EJD F00 F01 F04 F5P FEDTE G-S G.N GNP GODZA GWYGA H.T H.X HF~ HGLYW HHZ HVGLF HZ~ IX1 J0M JPC KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M6Q MEWTI MK4 MRFUL MRSTM MSFUL MSSTM MXFUL MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG P2P P2W P2X P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO RJQFR ROL RWI RX1 RYL SAMSI SUPJJ UB1 V8K VH1 W8V W99 WBFHL WBKPD WH7 WIB WIH WIK WJL WOHZO WQJ WRC WUP WWP WXSBR WYISQ XG1 XPP XV2 YCJ YHZ ZXP ZZTAW ~02 ~IA ~KM ~WT CGR CUY CVF ECM EIF NPM AAMNL AAYXX CITATION 7ST 7TK 7U7 C1K K9. SOI 8FD FR3 KR7 |
ID | FETCH-LOGICAL-c5522-57bd0bcda4d2f4a9b0511794b25518759510d0fb563828feed79f6724d3195853 |
IEDL.DBID | 33P |
ISSN | 0260-437X |
IngestDate | Fri Aug 16 09:57:03 EDT 2024 Fri Aug 16 07:14:19 EDT 2024 Thu Oct 10 22:22:04 EDT 2024 Thu Nov 21 20:50:18 EST 2024 Sat Sep 28 08:06:53 EDT 2024 Sat Aug 24 01:18:06 EDT 2024 Wed Oct 30 09:52:57 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Language | English |
License | Copyright © 2012 John Wiley & Sons, Ltd. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c5522-57bd0bcda4d2f4a9b0511794b25518759510d0fb563828feed79f6724d3195853 |
Notes | ark:/67375/WNG-8LMXRSZC-M ArticleID:JAT2732 istex:442A8DE7030EE145EDCC4C219B7A6E0A992DACCC ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 22407932 |
PQID | 1434888939 |
PQPubID | 105373 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_1753534152 proquest_miscellaneous_1439221425 proquest_journals_1434888939 crossref_primary_10_1002_jat_2732 pubmed_primary_22407932 wiley_primary_10_1002_jat_2732_JAT2732 istex_primary_ark_67375_WNG_8LMXRSZC_M |
PublicationCentury | 2000 |
PublicationDate | May 2013 |
PublicationDateYYYYMMDD | 2013-05-01 |
PublicationDate_xml | – month: 05 year: 2013 text: May 2013 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Bognor Regis |
PublicationSubtitle | JAT |
PublicationTitle | Journal of applied toxicology |
PublicationTitleAlternate | J. Appl. Toxicol |
PublicationYear | 2013 |
Publisher | Blackwell Publishing Ltd Wiley Subscription Services, Inc |
Publisher_xml | – name: Blackwell Publishing Ltd – name: Wiley Subscription Services, Inc |
References | Final Rules: Animal Welfare Standards; 9 CFR Part 3. 15 February 1991. Fed. Reg. 55(32): 6426-6505. US EPA. 1998. Health Effects Test Guidelines. OPPTS 870.3100 90-Day Oral Toxicity in Rodents. EPA 712-C-98-199. US Environmental Protection Agency: Washington, DC. Colacci A, Arfellini G, Mazzullo M, Prodi G, Grilli S. 1985. The covalent binding of bromobenzene with nucleic acids. Toxicol. Pathol. 13: 276-282. Final Rules: Animal Welfare; 9 CFR Parts 1 and 2. 31 August 1989. Fed. Reg. 54(168): 36112-36163. NRC. 1996. Guide for the Care and Use of Laboratory Animals. The National Academies Press: Washington, DC. Kluwe WM, Maronpot RR, Greenwell A, Harrington F. 1984. Interactions between bromobenzene dose, glutathione concentrations, and organ toxicities in single- and multiple-treatment studies. Fundam. Appl. Toxicol. 4: 1019-1028. US EPA. 2005. Guidelines for Carcinogen Risk Assessment. EPA/630/P-03/001B. Risk Assessment Forum, US Environmental Protection Agency: Washington, DC. Mohtashamipur E, Triebel R, Straeter H, Norpoth K. 1987. The bone marrow clastogenicity of eight halogenated benzenes in male NMRI mice. Mutagenesis 2(2): 111-113. US EPA. 1984. Health and Environmental Effects Profile for Bromobenzenes. EPA/600/X-84/128 (NTIS PB88137757). US Environmental Protection Agency: Washington, DC. 1987; 2 1989; 54 1984; 4 1991; 55 1981b 1981a 1985b 1976 1998 2009 1985a 1986 1996 1985d 1985c 1984 2005 1985; 13 US EPA (e_1_2_6_17_1) 1984 Final Rules: Animal Welfare Standards (e_1_2_6_4_1) 1991; 55 e_1_2_6_9_1 e_1_2_6_8_1 NRC (e_1_2_6_10_1) 1996 e_1_2_6_5_1 e_1_2_6_7_1 e_1_2_6_6_1 e_1_2_6_13_1 e_1_2_6_14_1 e_1_2_6_11_1 US EPA (e_1_2_6_20_1) 2009 e_1_2_6_2_1 Final Rules: Animal Welfare (e_1_2_6_3_1) 1989; 54 e_1_2_6_12_1 US EPA (e_1_2_6_18_1) 1998 e_1_2_6_15_1 e_1_2_6_16_1 US EPA (e_1_2_6_19_1) 2005 |
References_xml | – year: 1986 – year: 2009 – year: 1984 – year: 1985c – year: 1985b – year: 1985d – volume: 54 start-page: 36112 issue: 168 year: 1989 end-page: 36163 article-title: 9 CFR Parts 1 and 2 publication-title: Fed. Reg. – year: 2005 – year: 1985a – year: 1981b – year: 1981a – volume: 55 start-page: 6426 issue: 32 year: 1991 end-page: 6505 article-title: 9 CFR Part 3 publication-title: Fed. Reg. – year: 1996 – volume: 13 start-page: 276 year: 1985 end-page: 282 article-title: The covalent binding of bromobenzene with nucleic acids publication-title: Toxicol. Pathol. – volume: 4 start-page: 1019 year: 1984 end-page: 1028 article-title: Interactions between bromobenzene dose, glutathione concentrations, and organ toxicities in single‐ and multiple‐treatment studies publication-title: Fundam. Appl. Toxicol. – volume: 2 start-page: 111 issue: 2 year: 1987 end-page: 113 article-title: The bone marrow clastogenicity of eight halogenated benzenes in male NMRI mice publication-title: Mutagenesis – year: 1976 – year: 1998 – ident: e_1_2_6_5_1 – volume-title: Guidelines for Carcinogen Risk Assessment year: 2005 ident: e_1_2_6_19_1 contributor: fullname: US EPA – volume-title: Health and Environmental Effects Profile for Bromobenzenes year: 1984 ident: e_1_2_6_17_1 contributor: fullname: US EPA – volume-title: Support of Summary Information on the Integrated Risk Information System (IRIS) year: 2009 ident: e_1_2_6_20_1 contributor: fullname: US EPA – ident: e_1_2_6_13_1 – ident: e_1_2_6_16_1 – ident: e_1_2_6_11_1 – ident: e_1_2_6_14_1 – volume: 54 start-page: 36112 issue: 168 year: 1989 ident: e_1_2_6_3_1 article-title: 9 CFR Parts 1 and 2 publication-title: Fed. Reg. contributor: fullname: Final Rules: Animal Welfare – ident: e_1_2_6_9_1 doi: 10.1093/mutage/2.2.111 – volume-title: Guide for the Care and Use of Laboratory Animals year: 1996 ident: e_1_2_6_10_1 contributor: fullname: NRC – ident: e_1_2_6_2_1 doi: 10.1177/019262338501300404 – ident: e_1_2_6_6_1 – ident: e_1_2_6_8_1 doi: 10.1016/0272-0590(84)90241-0 – ident: e_1_2_6_7_1 – ident: e_1_2_6_15_1 – volume-title: Health Effects Test Guidelines. OPPTS 870.3100 90‐Day Oral Toxicity in Rodents year: 1998 ident: e_1_2_6_18_1 contributor: fullname: US EPA – volume: 55 start-page: 6426 issue: 32 year: 1991 ident: e_1_2_6_4_1 article-title: 9 CFR Part 3 publication-title: Fed. Reg. contributor: fullname: Final Rules: Animal Welfare Standards – ident: e_1_2_6_12_1 |
SSID | ssj0009928 |
Score | 2.0849123 |
Snippet | ABSTRACT
Male Fischer 344 (F344) rats were exposed to bromobenzene (BB) for 5 days and 2, 4 and 13 weeks. BB was administered by gavage (corn oil vehicle) at... Male Fischer 344 (F344) rats were exposed to bromobenzene (BB) for 5 days and 2, 4 and 13 weeks. BB was administered by gavage (corn oil vehicle) at doses of... Male Fischer 344 (F344) rats were exposed to bromobenzene (BB) for 5days and 2, 4 and 13weeks. BB was administered by gavage (corn oil vehicle) at doses of 0,... |
SourceID | proquest crossref pubmed wiley istex |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 370 |
SubjectTerms | Administration, Oral Alterations Animals Blood Body weight Body Weight - drug effects bromobenzene Bromobenzenes - toxicity Corn Oil - chemistry Dosage dose-response Dose-Response Relationship, Drug Endpoint Determination Hepatocytes - drug effects hepatotoxicity Hydrocarbons Incidence Liver Liver - drug effects Liver - metabolism Male Males No-Observed-Adverse-Effect Level Organ Size - drug effects Rats Rats, Inbred F344 Rodents time course Toxicity Toxicity Tests, Subchronic |
Title | Subchronic hepatotoxicity evaluation of bromobenzene in Fischer 344 rats |
URI | https://api.istex.fr/ark:/67375/WNG-8LMXRSZC-M/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjat.2732 https://www.ncbi.nlm.nih.gov/pubmed/22407932 https://www.proquest.com/docview/1434888939 https://search.proquest.com/docview/1439221425 https://search.proquest.com/docview/1753534152 |
Volume | 33 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Nb9QwELVKe0FCUAq0S1tkJLSnhmb9sUl6q9oue6DVihax4mL5IxZLpQQ1u1LbX98Ze7NRJUBInHKIozj2vJk3jueZkA-WW5dyDsZb5joRNisTPfA-GXJRDpiTAx8W3MaX2cU0Pz1DmZyjthYm6kOsFtwQGcFfI8C1aQ470dCfev4RYi-6X0gSQvUGn3R6u0U4VhUVsxLBs2mrO5uyw_bBR5FoAwf19nc08zFrDWFn9OJ_OrxJni_JJj2O1vGSrJXVFulPolr13QG96oqvmgPap5NOx_puizyLS3o0Viq9ImNwMjZq6dIfEMXm9by-nVmg8bTTDKe1pwa3-Jmyugc_SmcVHc0aNA3KhaBgcM1r8nV0dnUyTpYHMSRWSkxWM-NSY50WjnmhCwNIRiAbhnpumUSW5lJvJICZ5R7Cblb4YcaE46hlI_kbsl7VVblDqPPWCQycUgjUzSlMrj2woNw7O_Qs7ZH37aSoX1FvQ0VlZaZgABUOYI_0w2ytGuiba9yflkn17eKTyj-fT79cfj9R5z2y106nWkKzgVyHg9MCmlbAu1a3AVT4p0RXZb0IbQqGYnTyL20g0ZMc-U-PbEdTWXUo5MlF6GmwiD9-igInjNe3_9pwlzxl4UAO3HK5R9bnN4tynzxp3OJdAMAD0VoFdg |
link.rule.ids | 315,782,786,1408,27933,27934,46064,46488 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEB5BewAJUSivQIFFQjnV1NlHbKunqm0IIokiGkTUy8r2etUUyUZ1IrX8emZ241iVACFx8sFjeb07j2_GO98CvM9FbkIhUHmLOA1kHhVB2rM26AtZ9LhRPesKbsOzaDKPT06JJuew6YXx_BCbghtZhvPXZOBUkD5oWUMv0-UHDL7of7dlH_WQ-jfEtGXcTdzBqsSZFUgRzRvm2ZAfNE_eikXbNK3XvwOat3GrCzyDnf8a8iN4uMab7MgryGO4U5S70J16wuqbfTZr-6_qfdZl05bK-mYXHviqHvPNSk9giH4m93S67AID2bJaVteLHJE8a2nDWWVZRrv8sqL8ia6ULUo2WNSkHUxIyVDn6qfwdXA6Ox4G67MYglwpylejzIRZblJpuJVpkqExky1nnCjdIkVAzYQ2U2jPPLYYeaPE9iMujSA6GyWewVZZlcULYMbmRlLsVFISdU6SxalFIBRbk_ctDzvwrlkV_cNTbmhPrsw1TqCmCexA1y3XRiC9-k5b1CKlv00-6ng0nn85Oz_W4w7sNeup19ZZY7ojUF8QqSX4rs1ttCv6WZKWRbVyMgknPjr1FxnM9ZQgCNSB515XNgNyqXLiRupU4o-fotEP0_Xlvwq-hXvD2XikR58mn1_Bfe7O56AdmHuwtbxaFa_hbm1Wb5w1_AJRzQme |
linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ3bb9MwFIePYJMQEuIyboUBRkJ9WljqS5PwhraVIraqYkNUe7ESO9Y6pGRaWmnjr-ccu2k0CRAST3mIozj2ufzs2J8B3hlhbCwEGm-Z5pE0SRnlA-eioZDlgFs1cH7CbXycTGbp_gFhcj60e2ECH2I94Uae4eM1OfiFdbsdNPQ8X7zH3Ivhd1OiCiduvhDTDrib-XNVCZkVSZHMWvBszHfbJ2-kok1q1avf6cybstXnndGD_6nxQ7i_UpvsYzCPR3CrrLagPw246usddtLtvmp2WJ9NO5D19RbcC3N6LGxVegxjjDImwHTZGaaxRb2or-YGdTzroOGsdqygNX5FWf3EQMrmFRvNG7INJqRkaHHNE_g2OjjZG0erkxgioxSNVpPCxoWxubTcyTwr0JXJkwtOQLdEkUyzsSsUejNPHebdJHPDhEsrCGajxFPYqOqqfA7MOmMlZU4lJYFzsiLNHcqg1FkzdDzuwdu2U_RFAG7ogFbmGhtQUwP2oO97a10gv_xBC9QSpb9PPun08Gj29fh0Tx_1YLvtTr3yzQYHOwKjFuq0DN-1vo1eRb9K8qqsl75MxolGp_5SBkd6SpAA6sGzYCrrCvmBcuZr6i3ij5-iMQrT9cW_FnwDd6b7I334efLlJdzl_nAOWn65DRuLy2X5Cm43dvna-8IvC6UIRA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Subchronic+hepatotoxicity+evaluation+of+bromobenzene+in+Fischer+344+rats&rft.jtitle=Journal+of+applied+toxicology&rft.au=Dodd%2C+Darol+E.&rft.au=Pluta%2C+Linda+J.&rft.au=Sochaski%2C+Mark+A.&rft.au=Banas%2C+Deborah+A.&rft.date=2013-05-01&rft.issn=0260-437X&rft.eissn=1099-1263&rft.volume=33&rft.issue=5&rft.spage=370&rft.epage=377&rft_id=info:doi/10.1002%2Fjat.2732&rft.externalDBID=10.1002%252Fjat.2732&rft.externalDocID=JAT2732 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0260-437X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0260-437X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0260-437X&client=summon |